| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 15.00 +18.60% on 04/11/25 |
Period Open: 17.28
| 17.79 unch on 04/22/25 | +0.51 (+2.95%) since 03/21/25 |
| 3-Month | 15.00 +18.60% on 04/11/25 |
Period Open: 16.95
| 17.79 unch on 04/22/25 | +0.84 (+4.96%) since 01/22/25 |
| 52-Week | 14.97 +18.84% on 04/30/24 |
Period Open: 15.60
| 20.88 -14.80% on 12/16/24 | +2.19 (+14.04%) since 04/22/24 |
Michael B Baboval, the Chief Risk Officer of $MNSB ($MNSB), sold 2,892 shares of the company on 11-21-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 39.7%...
/PRNewswire/ -- MainStreet Bancshares, Inc. (Nasdaq: MNSB & MNSBP), the holding company for MainStreet Bank, announces the launch of Avenu's fully integrated...
/PRNewswire/ -- MainStreet Bancshares, Inc. (Nasdaq: MNSB & MNSBP), the holding company for MainStreet Bank, reported net income of $6.9 million for the...
/PRNewswire/ -- MainStreet Bancshares, Inc. (Nasdaq: MNSB & MNSBP), the holding company for MainStreet Bank, reported record net income of $8.2 million for the...
/PRNewswire/ -- MainStreet Bancshares, Inc. (Nasdaq: MNSB & MNSBP), the holding company for MainStreet Bank, announced two key appointments to its technology...
/PRNewswire/ -- The board of directors of MainStreet Bancshares Inc. (Nasdaq: MNSB) and (Nasdaq: MNSBP), the parent company of MainStreet Bank, declared a cash...
/PRNewswire/ -- MainStreet Bancshares, Inc. (Nasdaq: MNSB & MNSBP), the holding company for MainStreet Bank, reported record net income of $26.7 million for...
/PRNewswire/ -- The board of directors of MainStreet Bancshares Inc., (NASDAQ: MNSB) the parent company of MainStreet Bank, declared a cash dividend of $0.10...
/PRNewswire/ -- MainStreet Bank, the wholly owned subsidiary of MainStreet Bancshares, Inc. (NASDAQ: MNSB) (NASDAQ: MNSBP), announced it has earned a second...
/PRNewswire/ -- MainStreet Bancshares, Inc. (Nasdaq: MNSB & MNSBP), the holding company for MainStreet Bank, said its net interest margin widened as rates...
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled...
Geneva, Switzerland , July 7 , 202 1 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced...
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 30 , 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today...
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual...
Geneva, Switzerland, June 17, 20 2 1 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced...
First patient s enrolled into multi-center U.S. study
Ge neva, Switzerland, May 24 , 20 2 1 – Addex Th e rapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery...
Data published in Neuropharmacology supports therapeutic role of dipraglurant in this important movement disorder
Ge neva, Switzerland, May 14 , 20 2 1 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled...
Geneva, Switzerland , July 7 , 202 1 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced...
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 30 , 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today...
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual...
Geneva, Switzerland, June 17, 20 2 1 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced...
First patient s enrolled into multi-center U.S. study
Ge neva, Switzerland, May 24 , 20 2 1 – Addex Th e rapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery...
Data published in Neuropharmacology supports therapeutic role of dipraglurant in this important movement disorder
Ge neva, Switzerland, May 14 , 20 2 1 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
| Symbol | %Holdings | 3M %Chg |
|---|---|---|
| MNSB | +4.96% | |
| Mainstreet Bank | ||
| SQLV | 0.27% | -19.45% |
| Royce Quant Small-Cap Quality Value ETF | ||
| BSVO | 0.05% | -19.10% |
| Ea Bridgeway Omni Small-Cap Value ETF | ||
| ARKC | 0.04% | -19.05% |
| Ark Active On-Chain Bitcoin Strategy ETF | ||
| ARKY | 0.04% | -22.76% |
| Ark Active Bitcoin Ethereum Strategy ETF | ||
| IWC | 0.03% | -19.36% |
| Micro-Cap Ishares ETF | ||
| 3rd Resistance Point | 19.23 |
| 2nd Resistance Point | 18.51 |
| 1st Resistance Point | 18.15 |
| Last Price | 17.79 |
| 1st Support Level | 17.07 |
| 2nd Support Level | 16.35 |
| 3rd Support Level | 15.99 |
| 52-Week High | 20.88 |
| Fibonacci 61.8% | 18.62 |
| Fibonacci 50% | 17.92 |
| Last Price | 17.79 |
| Fibonacci 38.2% | 17.23 |
| 52-Week Low | 14.97 |
